Patents by Inventor Miriam E.C. Hancock
Miriam E.C. Hancock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080248507Abstract: Disclosed are methods and compositions for identifying malignant tumors that overexpress the c-erbB-2 oncogene. Assays useful for diagnosis and prognosis of neoplastic disease are provided which detect the external domain of c-erbB-2, the glycoprotein gp75 and quantitate the level of gp75 in the biological fluids of mammals carrying a tumor burden. Further disclosed are recombinant, synthetically and otherwise biologically produced novel proteins and polypeptides which are encoded by the external domain DNA sequence of the c-erbB-2 oncogene (the gp75 gene) or fragments thereof. Such gp75 proteins and polypeptides are useful as vaccines, therapeutically in the treatment of cancer either alone or in combination with chemotherapeutic agents. Also disclosed are antibodies to such gp75 proteins and polypeptides which are useful diagnostically and therapeutically. Still further disclosed are test kits embodying the assays of this invention.Type: ApplicationFiled: February 1, 2007Publication date: October 9, 2008Inventors: Miriam E.C. Hancock, John J. Monahan, Beatrice Claudia Langton
-
Patent number: 7282345Abstract: Disclosed are methods and compositions for identifying malignant tumors that overexpress the c-erbB-2 oncogene. Assays useful for diagnosis and prognosis of neoplastic disease are provided which detect the external domain of c-erbB-2, the glycoprotein gp75 and quantitate the level of gp75 in the biological fluids of mammals carrying a tumor burden. Further disclosed are recombinant, synthetically and otherwise biologically produced novel proteins and polypeptides which are encoded by the external domain DNA sequence of the c-erbB-2 oncogene (the gp75 gene) or fragments thereof. Such gp75 proteins and polypeptides are useful as vaccines, therapeutically in the treatment of cancer either alone or in combination with chemotherapeutic agents. Also disclosed are antibodies to such gp75 proteins and polypeptides which are useful diagnostically and therapeutically. Still further disclosed are test kits embodying the assays of this invention.Type: GrantFiled: November 29, 1993Date of Patent: October 16, 2007Assignee: Schering AGInventors: Miriam E. C. Hancock, John J. Monahan, Beatrice Claudia Langton
-
Patent number: 6884418Abstract: This invention is directed toward novel synergistic combinations of ligand-mimicking agents specific to the c-erbB-2 protein and anti-neoplastic drugs or agents, which can be used to treat a mammalian host, usually a human, suspected of having cancer or tumor cells by administering the combination in a therapeutically- or synergistically-effective amount. The drug combinations cytotoxic to tumor cells comprise an anti-neoplastic agent and a molecule, that is not conjugated to the anti-neoplastic agent, that binds the tumor cells and induces an increase in the phosphorylation of c-erbB-2 protein when placed in contact with the tumor cells. Alternatively, the drug combination cytotoxic to tumor cells may comprise an anti-neoplastic agent and a molecule, that is not conjugated to the anti-neoplastic agent, that binds the tumor cells and causes down modulation or internalization of c-erbB-2 protein. The anti-neoplastic drug is preferably an alkylating agent, most preferably cisplatin.Type: GrantFiled: January 18, 1991Date of Patent: April 26, 2005Assignee: Berlex Laboratories, Inc.Inventors: Laura K. Shawver, John W. Brandis, Elaina Mann, Miriam E.C. Hancock, Ronald P. Mischak, John J. Monahan
-
Publication number: 20020155527Abstract: Disclosed are methods and compositions for identifying malignant tumors that overexpress the c-erbB-2 oncogene. Assays useful for diagnosis and prognosis of neoplastic disease are provided which detect the external domain of c-erbB-2, the glycoprotein gp75 and quantitate the level of gp75 in the biological fluids of mammals carrying a tumor burden.Type: ApplicationFiled: January 26, 2001Publication date: October 24, 2002Applicant: Triton BioSciences, Inc.Inventors: Susan G. Stuart, John J. Monahan, Beatrice Claudia Langton, Miriam E. C. Hancock, Lorrine A. Chao, Peter Bluford
-
Patent number: 6123939Abstract: This invention is directed toward novel synergistic combinations of ligand-mimicking agents specific to the c-erbB-2 protein and anti-neoplastic drugs or agents, which can be used to treat a mammalian host, usually a human, suspected of having cancer or tumor cells by administering the combination in a therapeutically- or synergistically-effective amount. The drug combinations cytotoxic to tumor cells comprise an anti-neoplastic agent and a molecule, that is not conjugated to the anti-neoplastic agent, that binds the tumor cells and induces an increase in the phosphorylation of c-erbB-2 protein when placed in contact with the tumor cells. Alternatively, the drug combination cytotoxic to tumor cells may comprise an anti-neoplastic agent and a molecule, that is not conjugated to the anti-neoplastic agent, that binds the tumor cells and causes down modulation or internalization of c-erbB-2 protein. The anti-neoplastic drug is preferably an alkylating agent, most preferably cisplatin.Type: GrantFiled: June 7, 1995Date of Patent: September 26, 2000Assignee: Berlex Laboratories, Inc.Inventors: Laura K. Shawver, John W. Brandis, Elaina Mann, Miriam E. C. Hancock, Ronald P. Mischak, John J. Monahan
-
Patent number: 4937182Abstract: An assay for determining the sensitivity of an individual patient tumor to particular chemotherapeutic drugs relies on growth of the neoplastic tumor cells in a mass culture. The mass culture medium provides metabolites essential for the growth of the cells, even in the presence of the particular drug being tested, which is usually an anti-metabolic drug. The mass culture of cells is exposed to a labelled analog of the drug, and the uptake of the labelled drug analog determined. By comparing the amount of the drug uptake by the neoplastic cells with that of the corresponding normal cells, drug sensitivity may be assessed. The method is particularly useful with fluorescently-labelled drugs where the uptake may be assessed by use of a fluorescence activated cell sorter.Type: GrantFiled: February 7, 1989Date of Patent: June 26, 1990Assignee: Peralta Cancer Research InstituteInventors: Miriam E. C. Hancock, Helene S. Smith, Adeline J. Hackett
-
Patent number: 4816395Abstract: As assay for determining the sensitivity of an individual patient tumor to particular chemotherapeutic drugs relies on growth of the neoplastic tumor cells in a mass culture. The mass culture medium provides metabolites essential for the growth of the cells, even in the presence of the particular drug being tested, which is usually an anti-metabolic drug. The mass culture of cells is exposed to a labelled analog of the drug, and the uptake of the labelled drug analog determined. By comparing the amount of the drug uptake by the neoplastic cells with that of the corresponding normal cells, drug sensitivity may be assessed. The method is particularly useful with fluorescently-labelled drugs where the uptake may be assessed by use of a fluorescence activated cell sorter.Type: GrantFiled: December 19, 1985Date of Patent: March 28, 1989Assignee: Peralta Cancer Research InstituteInventors: Miriam E. C. Hancock, Helene S. Smith, Adeline J. Hackett